Sentences with phrase «safety at the current price»

As to Liberty Ventures I think there is little margin of safety at current prices.

If the result of the changes is that you no longer have a margin of safety at the current price, the stock should be sold.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

There's no word on price — and Intelligent Drive and other safety tech will be optional — but the current C - Class line starts at $ 35,800.

Among these are avoiding companies with too much debt; looking for a margin of safety, such as over - 2.0 current ratio (current assets dividend by current liabilities); and seeking stocks trading at low price - earnings ratios and low price - to - book - value ratios.

I always thought that investors only bought shares in a company when it traded at prices significantly below its current intrinsic value in order to create a margin of safety in the event of something going wrong.

Shares are trading for less than 10 % above the 52 - week low and I think a comfortable margin of safety exists at the current price.

In addition to potentially sizable appreciation from present levels fueled by both impending catalysts and growing cash flows, at current prices, RDI has an enormous «margin of safety» both from the value of Reading's huge landholdings in Australia, New Zealand and the United States, as well as an imputed compelling cheap valuation of its cinema segment, by taking out any conservative value for real estate.

When analyzing my portfolio I look at each individual asset and ask myself; is the current price an excellent value, does it provide a margin of safety?